Skip to Content


Pipeline & Partners

Intarcia is developing its Medici Drug Delivery System™, bridging technology and medicine, to transform the treatment and prevention of chronic disease.

ITCA 650/12M

Intarcia’s pre-clinical candidate, ITCA 650/12M (once-yearly exenatide implant), for the treatment of type 2 diabetes (“T2D”). Exenatide, the active agent of ITCA 650/12M, is a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) is presently being developed for the treatment of T2D by delivering annual dosing of exenatide via the Medici System. 

Next Generation Approaches to Diabetes, Obesity and NASH

Intarcia has made significant strides to advance a pipeline of drug candidates, specifically tailored for delivery via the Medici System. Development is focused on "next generation" combination therapies for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH), as well as a treatment for type 1 diabetes (“T1D”), from internally discovered and developed drug candidates. 

Bill & Melinda Gates Foundation – HIV Pre-exposure Prophylaxis (PrEP)

Intarcia is working to develop once-yearly anti-HIV prophylactic therapy for delivery via the Medici System through a collaboration with the Bill & Melinda Gates Foundation. The goal is to help prevent the spread of HIV in Sub-Saharan Africa and other regions impacted by the HIV epidemic.

Partners and science behind the next generation of medicine delivery across multiple therapeutic categories.
Back to top